2 research outputs found
Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
For more than two years after the emergence of COVID-19 (Coronavirus Disease-2019), significant regional differences in morbidity persist. These differences clearly show lower incidence rates in several regions of the African and Asian continents. The work reported here aimed to test the hypothesis of a pre-pandemic natural immunity acquired by some human populations in central and western Africa, which would, therefore, pose the hypothesis of an original antigenic sin with a virus antigenically close to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). To identify such pre-existing immunity, sera samples collected before the emergence of COVID-19 were tested to detect the presence of IgG reacting antibodies against SARS-CoV-2 proteins of major significance. Sera samples from French blood donors collected before the pandemic served as a control. The results showed a statistically significant difference of antibodies prevalence between the collected samples in Africa and the control samples collected in France. Given the novelty of our results, our next step consists in highlighting neutralizing antibodies to evaluate their potential for pre-pandemic protective acquired immunity against SARS-CoV-2. In conclusion, our results suggest that, in the investigated African sub-regions, the tested populations could have been potentially and partially pre-exposed, before the COVID-19 pandemic, to the antigens of a yet non-identified Coronaviruses
Identification of the PfK13 mutations R561H and P441L in Democratic Republic of Congo (DRC).
BACKGROUND: Partial artemisinin resistance, mediated by P. falciparum K13 (PfK13) mutations, has been confirmed in certain areas of East Africa which are historically associated with high-level antimalarial resistance. DRC borders these areas in the East. OBJECTIVES: To determine the prevalence of resistance markers in six national malaria control programme (NMCP) surveillance sites; Boende, Kabondo, Kapolowe, Kimpese, Mikalayi and Rutshuru. METHODS: The SNPs in P. falciparum genes PfK13, Pfdhfr, Pfdhps, Pfmdr1 and Pfcrt were assessed using targeted NGS of isolates collected at enrolment in therapeutic efficacy studies. RESULTS: PfK13 SNPs were detected in two samples; in Kabondo (R561H) and in Rutshuru (P441L), both areas near Uganda and Rwanda. The Pfdhps ISGEGA haplotype, associated with reduced SP chemoprevention efficacy, ranged from 0.8% in Mikalayi (central DRC) to 42.2% in Rutshuru (East DRC). CONCLUSIONS: R561H and P441L observed in eastern DRC are a concern, as they are associated with delayed ACT-clearance and candidate marker of resistance, respectively. This is consistent with previous observations of shared drug resistance profiles in parasites of that region with bordering areas of Rwanda and Uganda. The likely circulation of parasites has important implications for the ongoing surveillance of partial artemisinin-resistant P. falciparum and for future efforts to mitigate its dispersal